Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Anemia management in the era of triple combination therapy for chronic HCV.

Jacobson IM, Kowdley KV, Kwo PY.

Gastroenterol Hepatol (N Y). 2012 Sep;8(9 Suppl 6):1-16.

2.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
3.

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators.

Hepatology. 2013 Mar;57(3):974-84. doi: 10.1002/hep.26096. Epub 2013 Feb 11.

PMID:
23081753
4.

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.

Sitole M, Silva M, Spooner L, Comee MK, Malloy M.

Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.

PMID:
23369368
5.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

6.

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.

Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Hepatol. 2013 Oct;59(4):667-74. doi: 10.1016/j.jhep.2013.05.017. Epub 2013 May 23.

PMID:
23707372
7.

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M.

Gastroenterology. 2014 Feb;146(2):430-41.e6. doi: 10.1053/j.gastro.2013.10.058. Epub 2013 Nov 1.

PMID:
24184810
8.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
9.

Anemia management in patients with chronic viral hepatitis C.

Hynicka LM, Heil EL.

Ann Pharmacother. 2013 Feb;47(2):228-36. doi: 10.1345/aph.1R513. Epub 2013 Feb 5. Review.

PMID:
23386076
10.

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC.

J Hepatol. 2014 Jan;60(1):78-86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.

PMID:
23994384
11.

Administration of low-dose epoetin-alpha facilitates adherence to ribavirin in triple therapy with pegylated interferon-alpha-2b and telaprevir.

Ishida H, Sakane S, Toyama T, Fukutomi K, Kimura K, Sugimoto A, Hibino K, Tamura T, Iwasaki T, Iwasaki R, Hasegawa H, Sakakibara Y, Yamada T, Nakazuru S, Mita E.

Hepatol Res. 2014 Oct;44(10):E84-91. doi: 10.1111/hepr.12224. Epub 2014 Jan 7.

PMID:
23957840
12.

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.

Asselah T.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):455-62. doi: 10.1016/j.bpg.2012.09.003.

PMID:
23199504
13.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

14.

Anemia in the treatment of hepatitis C virus infection.

Sulkowski MS.

Clin Infect Dis. 2003;37 Suppl 4:S315-22.

15.

[Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis].

Yuan XL, Li MY, Zhang DZ.

Zhonghua Gan Zang Bing Za Zhi. 2012 May;20(5):357-62. doi: 10.3760/cma.j.issn.1007-3418.2012.05.011. Chinese.

PMID:
22971281
16.

[Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].

He LL, Chen Z, Chen Y, Xu H, Tang H, Lei BJ, Lei XZ.

Zhonghua Gan Zang Bing Za Zhi. 2011 Jan;19(1):34-7. doi: 10.3760/cma.j.issn.1007-3418.2011.01.010. Chinese.

PMID:
21272456
17.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
18.

Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.

Burney T, Dusheiko G.

Expert Rev Anti Infect Ther. 2011 Feb;9(2):151-60. doi: 10.1586/eri.10.153. Epub 2010 Dec 14. Review.

PMID:
21143041
19.

[Retreatment options for patients with chronic hepatitis C].

Hrstić I, Ostojić R, Vucelić B.

Acta Med Croatica. 2009 Dec;63(5):417-22. Croatian.

PMID:
20198901
20.

How to optimize HCV therapy in genotype 1 patients with cirrhosis.

Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP.

Liver Int. 2013 Feb;33 Suppl 1:46-55. doi: 10.1111/liv.12067. Review.

PMID:
23286846
Items per page

Supplemental Content

Write to the Help Desk